This company has been acquired
La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Freeline Therapeutics Holdings Performance dei guadagni passati
Il passato criteri di controllo 0/6
Freeline Therapeutics Holdings's earnings have been declining at an average annual rate of -6.3%, while the Biotechs industry saw earnings growing at 16.4% annually. Revenues have been growing at an average rate of 112.4% per year.
Informazioni chiave
-6.3%
Tasso di crescita degli utili
43.9%
Tasso di crescita dell'EPS
| Biotechs Crescita del settore | 17.0% |
| Tasso di crescita dei ricavi | 112.4% |
| Rendimento del capitale proprio | -166.2% |
| Margine netto | -8,027.7% |
| Ultimo aggiornamento sui guadagni | 30 Sep 2023 |
Aggiornamenti sulle prestazioni recenti
Nessun aggiornamento
Recent updates
Calculating The Intrinsic Value Of Freeline Therapeutics Holdings plc (NASDAQ:FRLN)
Jul 13
Here's Why Freeline Therapeutics Holdings (NASDAQ:FRLN) Must Use Its Cash Wisely
Apr 11Here's Why Freeline Therapeutics Holdings (NASDAQ:FRLN) Must Use Its Cash Wisely
Dec 20We're Keeping An Eye On Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Rate
Aug 30Freeline gains as NEJM publishes long-term data for hemophilia therapy
Jul 21Is Freeline Therapeutics Holdings (NASDAQ:FRLN) In A Good Position To Invest In Growth?
May 05Will Freeline Therapeutics Holdings (NASDAQ:FRLN) Spend Its Cash Wisely?
Jan 13Companies Like Freeline Therapeutics Holdings (NASDAQ:FRLN) Could Be Quite Risky
Sep 30Here's Why We're Watching Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Situation
Jun 03What Kind Of Shareholders Hold The Majority In Freeline Therapeutics Holdings plc's (NASDAQ:FRLN) Shares?
Feb 18
Ripartizione dei ricavi e delle spese
Come Freeline Therapeutics Holdings guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
| Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 30 Sep 23 | 1 | -50 | 32 | 34 |
| 30 Jun 23 | 1 | -53 | 40 | 37 |
| 31 Mar 23 | 0 | -61 | 39 | 47 |
| 31 Dec 22 | 0 | -89 | 42 | 53 |
| 30 Sep 22 | 0 | -101 | 43 | 66 |
| 30 Jun 22 | 0 | -117 | 41 | 80 |
| 31 Mar 22 | 0 | -132 | 46 | 86 |
| 31 Dec 21 | 0 | -140 | 45 | 93 |
| 30 Sep 21 | 0 | -144 | 49 | 86 |
| 30 Jun 21 | 0 | -138 | 39 | 85 |
| 31 Mar 21 | 0 | -115 | 33 | 70 |
| 31 Dec 20 | 0 | -96 | 26 | 61 |
| 30 Sep 20 | 0 | -73 | 20 | 53 |
| 30 Jun 20 | 0 | -63 | 22 | 40 |
| 31 Mar 20 | 0 | -58 | 17 | 41 |
| 31 Dec 19 | 0 | -54 | 17 | 36 |
| 31 Dec 18 | 0 | -33 | 7 | 26 |
| 30 Sep 17 | 0 | -17 | 7 | 11 |
Guadagni di qualità: FRLN is currently unprofitable.
Margine di profitto in crescita: FRLN is currently unprofitable.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: FRLN is unprofitable, and losses have increased over the past 5 years at a rate of 6.3% per year.
Accelerare la crescita: Unable to compare FRLN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Guadagni vs Settore: FRLN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.1%).
Rendimento del capitale proprio
ROE elevato: FRLN has a negative Return on Equity (-166.22%), as it is currently unprofitable.